The extra domain A (EDA)-containing fibronectin (EDA-FN), an alternatively spliced form of the extracellular matrix protein fibronectin, is predominantly expressed in various malignancies but not in normal tissues. In the present study, we investigated the potential pro-lymphangiogenesis effects of extra domain A (EDA)-mediated vascular endothelial growth factor-C (VEGF-C) secretion in colorectal carcinoma (CRC). We detected the expressions of EDA and VEGF-C in 52 human colorectal tumor tissues and their surrounding mucosae by immunohistochemical analysis, and further tested the correlation between the expressions of these two proteins in aforementioned CRC tissues. Both EDA and VEGF-C were abundantly expressed in the specimens of human CRC tissues. And VEGF-C was associated with increased expression of EDA in human CRC according to linear regression analysis. Besides, EDA expression was significantly correlated with lymph node metastasis, tumor differentiation and clinical stage by clinicopathological analysis of tissue microarrays containing tumor tissues of 115 CRC patients. Then, human CRC cell SW480 was transfected with lentivectors to elicit expression of shRNA against EDA (shRNA-EDA), and SW620 was transfected with a lentiviral vector to overexpress EDA (pGC-FU-EDA), respectively. We confirmed that VEGF-C was upregulated in EDA-overexpressed cells, and downregulated in shRNA-EDA cells. Moreover, a PI3K-dependent signaling pathway was found to be involved in EDA-mediated VEGF-C secretion. The in vivo result demonstrated that EDA could promote tumor growth and tumor-induced lymphangiogenesis in mouse xenograft models. Our findings provide evidence that EDA could play a role in tumor-induced lymphangiogenesis via upregulating autocrine secretion of VEGF-C in colorectal cancer, which is associated with the PI3K/Akt-dependent pathway.
References
[1]
Sundlisaeter E, Dicko A, Sakariassen P？, Sondenaa K, Enger P？, et al. (2007) Lymphangiogenesis in colorectal cancer--prognostic and therapeutic aspects. Int J Cancer 121: 1401–1409.
[2]
Saad RS, Lindner JL, Liu Y, Silverman JF (2009) Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma. Am J Clin Pathol 131: 92–98.
[3]
Liu HT, Ma R, Yang QF, Du G, Zhang CJ (2009) Lymphangiogenic characteristics of triple negativity in node-negative breast cancer. Int J Surg Pathol 17: 426–431.
[4]
Clasper S, Royston D, Baban D, Cao Y, Ewers S, et al. (2008) A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res 68: 7293–7303.
[5]
Barresi V, Reggiani-Bonetti L, Di Gregorio C, De Leon MP, Barresi G (2011) Lymphatic vessel density and its prognostic value in stage I colorectal carcinoma. J Clin Pathol 64: 6–12.
[6]
Duff SE, Li C, Renehan A, O’Dwyer ST, Kumar S (2003) Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. Int J Oncol 22: 339–343.
[7]
Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, et al. (2008) Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14: 62–66.
[8]
Parr C, Jiang WG (2003) Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Int J Oncol 23: 533–539.
[9]
Royston D, Jackson DG (2009) Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma. J Pathol 217: 608–619.
[10]
Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, et al. (2003) Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 63: 713–722.
[11]
Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yl？-Herttuala S, et al. (2001) Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61: 1786–1790.
[12]
Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, et al. (2002) Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 62: 1315–1320.
[13]
Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, et al. (2001) Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672–682.
[14]
Achen MG, McColl BK, Stacker SA (2005) Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 7: 121–127.
[15]
Pepper MS (2001) Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer Res 7: pp. 462–468.
[16]
Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, et al. (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122: 2405–2413.
[17]
Romberger DJ (1997) Fibronectin. Int J Biochem Cell Biol 29: 939–943.
[18]
McFadden JP, Baker BS, Powles AV, Fry L (2010) Psoriasis and extra domain A fibronectin loops. Br J Dermatol 163: 5–11.
[19]
van der Straaten HM, Canninga-van Dijk MR, Verdonck LF, Castigliego D, Borst HP, et al. (2004) Extra-domain-A fibronectin: a new marker of fibrosis in cutaneous graft-versus-host disease. J Invest Dermatol 123: 1057–1062.
[20]
Ou JJ, Wu F, Liang HJ (2010) Colorectal tumor derived fibronectin alternatively spliced EDA domain exserts lymphangiogenic effect on human lymphatic endothelial cells. Cancer Biology & Therapy 9: 186–191.
[21]
Tang Y, Zhang D, Fallavollita L, Brodt P (2003) Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res 63: 1166–1171.
[22]
Oliver G, Detmar M (2002) The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 16: 773–783.
[23]
Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, et al. (2008) Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13: 331–342.
[24]
Bahram F, Claesson-Welsh L (2010) VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology 17: 253–261.
[25]
Girling JE, Rogers PA (2009) Regulation of endometrial vascular remodelling: role of the vascular endothelial growth factor family and the angiopoietin-TIE signalling system. Reproduction 138: 883–893.
[26]
Saintigny P, Kambouchner M, Ly M, Gomes N, Sainte-Catherine O, et al. (2007) Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer 58: 205–213.
[27]
Chang L, Kaipainen A, Folkman J (2002) Lymphangiogenesis new mechanisms. Ann N Y Acad Sci 979: 111–119.
[28]
Su JL, Chen PS, Chien MH, Chen PB, Chen YH, et al. (2008) Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell 13: 557–560.
[29]
Tammela T, Alitalo K (2010) Lymphangiogenesis: Molecular Mechanisms and Future Promise. Cell 140: 460–476.
[30]
Enholm B, Paavonen K, Ristim？ki A, Kumar V, Gunji Y, et al. (1997) Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14: 2475–2483.
[31]
Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in angiogenesis and lymphangiogenesis. Nature Reviews Cancer 8: 604–617.
[32]
Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH (2004) Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 279: 45643–45651.
[33]
Saji M, Ringel MD (2010) The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321: 20–28.
[34]
West KA, Castillo SS, Dennis PA (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234–248.
[35]
Goc A, Al-Husein B, Kochuparambil ST, Liu J, Heston WW, et al. (2011) PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. International Journal of Oncology 38: 267–277.
[36]
Duan GJ, Yan XC, Bian XW, Li J, Chen X (2004) [The significance of beta-catenin and matrix metalloproteinase-7 expression in colorectal adenoma and carcinoma]. Zhonghua bing li xue za zhi Chinese journal of pathology 33: 518–522.
